Key facts
- Parallel Bio’s last known valuation is $71.5M (Jun 2025).
- It has raised $24.6M across 2 recorded rounds; the latest was Later Stage VC (Series A1) ($20.0M) in Jun 2025.
- Notable investors include Y Combinator, Gaingels, Metaplanet Holdings, Asymmetry Ventures, Jeff Dean — 24 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Parallel Bio
Funding rounds
2 roundsAbout Parallel Bio
Operator of a biotechnology company intended to design and engineer tools to change the way diseases are cured. The company's platform deploys human immune organoids to rapidly accelerate the discovery and development of immunotherapies, cell therapies, antibody therapies, and vaccines, enabling medical professionals to have access to novel insights into human biology.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 10
- Website
- parallel.bio/
- Ownership
- Privately Held (backing)
Parallel Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Parallel Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Parallel Bio in its N-PORT filings yet. We sweep new filings monthly.